NPPA Raises Anti-Rabies Immunoglobulin Price, Fixes Retail Rates of 39 Drug Formulations

July 12, 2026

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has increased the retail price of anti-rabies immunoglobulin while fixing the retail prices of 39 drug formulations used in the treatment of conditions including hypertension, diabetes, HIV, heart disease and eye infections.

The decision was taken during the authority’s 148th meeting and issued through a gazette notification under the Drugs (Prices Control) Order (DPCO).

Anti-Rabies Immunoglobulin Price Increased by 6.49%

According to the notification, the retail price of anti-rabies immunoglobulin has been revised to Rs 119.48 per millilitre (ml) from the earlier Rs 112.19 per ml.

This marks an increase of 6.49 per cent in the notified retail price.

The revision comes after NPPA’s decision in March this year to allow a 0.64956 per cent annual increase in the prices of medicines listed under the National List of Essential Medicines (NLEM) based on changes in the Wholesale Price Index (WPI).

Retail Prices Fixed for Medicines Used in Major Treatments

The pricing regulator also fixed retail rates for several commonly used medicines to ensure availability and affordability for patients.

Among the newly fixed prices:

• A combination tablet of amlodipine, bisoprolol and telmisartan, used for hypertension treatment, has been priced at Rs 14.74 per tablet.
• A cardiology medicine containing clopidogrel, aspirin and atorvastatin, prescribed to reduce the risk of heart attacks and strokes, has been fixed at Rs 6.37 per capsule.
• Nepafenac and moxifloxacin ophthalmic solution, used for eye infections, has been priced at Rs 68.64 per ml.

Companies Charging Higher Prices May Face Action

The NPPA notification stated that manufacturers and marketing companies charging prices above the approved retail rates will have to deposit the excess amount along with applicable interest under the provisions of the DPCO.

The authority said fixing and revising medicine prices is a regular regulatory exercise aimed at controlling drug prices and ensuring that essential medicines remain affordable for consumers.

Five-Year Price Control Exemption Granted to Pneumococcal Vaccine

In a separate decision, NPPA granted a five-year exemption from price control to Pneubevax 14, India’s first 14-valent Pneumococcal Polysaccharide Conjugate Vaccine developed and manufactured by Hyderabad-based Biological E.

The authority said the vaccine qualified for exemption under Paragraphs 32(i) and 32(ii) of DPCO, 2013, as it is covered by a granted patent and developed through indigenous research and development.

Under these provisions, a patented new drug developed domestically and not manufactured elsewhere receives exemption from price control for five years from the start of commercial production in India.

NPPA has directed Biological E to submit details related to the vaccine’s commercial production date, marketing date, price to retailer (PTR) and maximum retail price (MRP).